64 results about "Lisinopril" patented technology

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

The invention relates to the field of biotechnology in the pharmaceutical industry, and discloses the preparation of an immobilized whole-cell catalyst and its application in the synthesis of a Puley intermediate (R)-2-hydroxy-4-phenyl-butyric acid. The recombinant cells containing the D-type lactate dehydrogenase gene and the formate dehydrogenase gene are established and fixed to prepare the immobilized whole cell catalyst. Using this catalyst to synthesize the intermediate (R)-2-hydroxy-4-phenyl-butyric acid of lisinopril, the reaction conditions are mild, the action is specific, and there are no by-products. It is used in medicine and food industries. value.

A stable pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutical acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the ACE inhibitor is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, cilazapril and combinations thereof; wherein the formation of an internal cyclization product, and/or ester hydrolysis product, and/or oxidation product, has been reduced or eliminated, and the weight percents are based on the total weight of the pharmaceutical composition. The stabilized pharmaceutical compositions of the invention exhibit a number of advantages as follows: (i) the ACE inhibitor or a pharmaceutical acceptable salt thereof present in the compositions is preserved from degradation; (ii) the compositions exhibit extended shelf-life under normal storage conditions; (iii) the effect of moisture on the compositions is minimized; (iv) the compositions exhibit minimal, if any, discoloration over a significant period of time; and (v) the compositions exhibit minimal, if any, instability when employed in the presence of colorants.

The invention relates to a lisinopril controlled-release tablet and a preparation method thereof, belonging to the field of pharmaceutic preparation technology and solving the problem that existing lisinpopril controlled-release tablet cannot delay release and release mildly. The tablet consists of core of the tablet containing lisinopril and a coating wrapped outside the core of the tablet, the core of the tablet containing the lisinopril comprises the following components by weight percent: 5.0%-20% of lisinopril, 25%-55% of framework material, 20%-50% of filler, and1.0%-3.0% of lubricant, the coating comprises the following components in weight percent: 60%-90% of water insoluble coating material and 10%-40% of pore-foaming agent. The method comprises the preparation of core of the tablet containing lisinpopril, the preparation of coating liquor, and the preparation of the tablet by wrapping the coating liquor outside the core of table so as to form the coating. The lisinopril controlled-release tablet can delay release and release mildly, and the method is simple and beneficial to industrialization.

Overexpression of angiotensin-converting enzyme (ACE) has been associated with a number of pathophysiologies, including those associated with cancer and the cardiovascular system. Thus, targeted imaging of ACE is of crucial importance for monitoring tissue ACE activity as well as treatment efficacy. To this end, lisinopril-coated gold nanoparticles were prepared to provide a new type of probe for targeted molecular imaging of ACE by tuned K-edge computed tomography (CT) imaging.

The invention relates to a kind of chemosynthesis method of N-[1(S)-ethoxy carbonyl-3-phenyl propyl]-L-alanine-N-hydroxy acid anhydride, which is the medicine midbody for synthesizing Pulitzer series medicine such as Enalapril, Ramipril, Lisinopril and so on. The invention uses couple (trichloromethyl) ester carbonate and N-[1(S)-ethoxy carbonyl-3-phenyl propyl]-L-alanine as row material, and get the product by reacting with catalyst action in organic solvent. This chemosynthesis method is a manufacturing method of N-[1(S)-ethoxy carbonyl-3-phenyl propyl]-L-alanine-N-hydroxy acid anhydride, which has acquirable raw material, low production cost, and no three wastes normally.

The invention discloses a prescription and a preparation technology of compound tablets containing amlodipine besylate and lisinopril. According to the invention, amlodipine besylate and lisinopril are adopted as active components, a tert-butyl alcohol solution is adopted as an adhesive, and the tablets are prepared through wet granulating and tabletting. The content uniformity of the compound tablets is relatively good. Lisinopril is stable in the preparation process, and the content of the related substances of lisinopril is low.

The invention discloses a method for separating lisinopril ester. The method comprises the following steps of: performing annular gap type centrifugal extraction on lisinopril ester-containing material liquid by using a two to eight-stage serial countercurrent centrifugal extraction system consisting of annular gap types centrifugal extractors and by taking an organic solvent as an extracting agent; and concentrating the obtained extract phase and recovering the organic solvent to obtain the lisinopril ester. Compared with the conventional production process, the method has the advantages of a small amount of solvent, stable quality, high extraction rate, short period, low three-waste energy consumption (waste water, waste gas and industrial residues), safe and reliable production, and high implementation value and social economic benefit.

The invention relates to a compound preparation for treating cardiovascular disease and in particular relates to a lisinopril compound preparation for treating cardiovascular disease. The lisinopril compound preparation comprises the following drugs in parts by weight: 2-6 parts of lisinopril, 0.8-2.8 parts of hydrochlorothiazide and 1.6-3.6 parts of levamlodipine besylate. According to an acting mechanism of giving full play to complementation of drugs by combined medication, the curative effect is increased, and the standard is quickly achieved, the rate of reaching the standard of blood pressure reaches 82%, and adverse effects related to increase of some dosage are reduced. The compound preparation has the characteristics of being quick to take effect, high in rate of reaching the standard of blood pressure, small in side effect and low in cost.

The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the prevention of cardiovascular diseases in high-risk populations.

The invention discloses a sustained and controlled-release transdermal patch containing lisinopril, and relates to the field of pharmaceutical preparations. The transdermal patch comprises a drug reservoir layer, a backing layer and a protective layer, wherein the drug reservoir layer is composed of the lisinopril, a reservoir substrate and a penetration enhancer. The drug reservoir layer of each dosage of the sustained and controlled-release transdermal patch consists of 10-80mg of the lisinopril in terms of effective dose; and in percentage by weight, the drug reservoir layer consists of 2.5-25% of the lisinopril, 70-97% of the reservoir substrate and 0.5-5% of the penetration enhancer. The sustained and controlled-release transdermal patch containing the lisinopril provided by the invention, in comparison with lisinopril normal tablets, capsules or oral sustained-release preparations on the current market, is uniform in drug release, concrete in curative effect and stable in quality.

The invention relates to a lisinopril intermediate, i.e., (S)-2-((S)-2,5-dioxo-4-(4-(2,2,2-trifluoroacetylamino)butyl)oxazolidin-3-yl)-4-phenylethyl butyrate and a purification method therefor. The method comprises the following steps: adding toluene into a crude lisinopril anhydride intermediate under nitrogen protection, carrying out heating, stirring and dissolved clarification, then, adding aC5-10 alkane solvent, carrying out heat preservation and stirring, then, carrying out suction filtration, and carrying out baking, thereby obtaining a product I. According to the purification method,homophenylalanine impurities can be effectively removed, total impurities are also reduced, the finished product quality is improved, and high-quality lisinopril can be stably obtained through processproduction.